Chunjing Li1, Fangpeng Shu2, Bin Lei2, Daojun Lv2, Shoubo Zhang3, Xiangming Mao4. 1. Department of Urology, Nanfang Hospital, Southern Medical University Guangzhou, Guangdong Province, China ; Department of Surgery, Women and Children's Hospital of Foshan Foshan, Guangdong, Province, China. 2. Department of Urology, Nanfang Hospital, Southern Medical University Guangzhou, Guangdong Province, China. 3. Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Armed Police Hospital, Guangzhou Medical University Guangzhou, Guangdong Province, China. 4. Department of Urology, Nanfang Hospital, Southern Medical University Guangzhou, Guangdong Province, China ; Department of Urology, Peking University Shenzhen Hospital, Shenzhen Pku-Hkust Medical Center Shenzhen, Guangdong Province, China.
Abstract
OBJECTIVE: This study is aimed to evaluate the expression of phosphoglycerate mutase 1 (PGAM1) in normal kidney and clear cell renal cell carcinoma (CCRCC), also to evaluate the correlation between PGAM1 expression and clinicopathological features in CCRCC. METHODS: PGAM1 expression was detected in 80 cases of normal kidney and 192 cases of CCRCC by immunohistochemistry (IHC). Meanwhile, PGAM1 expression measured in 8 cases of CCRCC and matched normal kidney tissues by Western blot. Then, the correlation between PGAM1 expression and clinicalpathological features was analyzed in CCRCC. RESULTS: IHC results exhibited that the high-expression rate of PGAM1 in CCRCC tissues was 45.8%, which was significantly higher than those in normal kidney tissues (32.5%, P=0.044). Meanwhile, PGAM1 expression in CCRCC was significantly greater compared with those in normal kidney by Western blot. Moreover, PGAM1 expression was significantly associated with age, tumor size and T stage in CCRCC. CONCLUSION: PGAM1 is highly expressed in CCRCC and correlated with clinicalpathological features, which may contribute to tumor formation and progression.
OBJECTIVE: This study is aimed to evaluate the expression of phosphoglycerate mutase 1 (PGAM1) in normal kidney and clear cell renal cell carcinoma (CCRCC), also to evaluate the correlation between PGAM1 expression and clinicopathological features in CCRCC. METHODS:PGAM1 expression was detected in 80 cases of normal kidney and 192 cases of CCRCC by immunohistochemistry (IHC). Meanwhile, PGAM1 expression measured in 8 cases of CCRCC and matched normal kidney tissues by Western blot. Then, the correlation between PGAM1 expression and clinicalpathological features was analyzed in CCRCC. RESULTS: IHC results exhibited that the high-expression rate of PGAM1 in CCRCC tissues was 45.8%, which was significantly higher than those in normal kidney tissues (32.5%, P=0.044). Meanwhile, PGAM1 expression in CCRCC was significantly greater compared with those in normal kidney by Western blot. Moreover, PGAM1 expression was significantly associated with age, tumor size and T stage in CCRCC. CONCLUSION:PGAM1 is highly expressed in CCRCC and correlated with clinicalpathological features, which may contribute to tumor formation and progression.
Authors: Sara Samaan; Heba W Z Khella; Andrew Girgis; Andreas Scorilas; Evi Lianidou; Manal Gabril; Sergey N Krylov; Michael Jewett; Georg A Bjarnason; Hala El-said; George M Yousef Journal: J Mol Diagn Date: 2014-12-31 Impact factor: 5.568
Authors: Matthew G Vander Heiden; Jason W Locasale; Kenneth D Swanson; Hadar Sharfi; Greg J Heffron; Daniel Amador-Noguez; Heather R Christofk; Gerhard Wagner; Joshua D Rabinowitz; John M Asara; Lewis C Cantley Journal: Science Date: 2010-09-17 Impact factor: 47.728
Authors: Taro Hitosugi; Lu Zhou; Shannon Elf; Jun Fan; Hee-Bum Kang; Jae Ho Seo; Changliang Shan; Qing Dai; Liang Zhang; Jianxin Xie; Ting-Lei Gu; Peng Jin; Masa Alečković; Gary LeRoy; Yibin Kang; Jessica A Sudderth; Ralph J DeBerardinis; Chi-Hao Luan; Georgia Z Chen; Susan Muller; Dong M Shin; Taofeek K Owonikoko; Sagar Lonial; Martha L Arellano; Hanna J Khoury; Fadlo R Khuri; Benjamin H Lee; Keqiang Ye; Titus J Boggon; Sumin Kang; Chuan He; Jing Chen Journal: Cancer Cell Date: 2012-11-13 Impact factor: 31.743
Authors: Heidi Högel; Krista Rantanen; Petra Miikkulainen; Tomi Suomi; Petri Kouvonen; Laura L Elo; Panu M Jaakkola Journal: Cancer Metab Date: 2017-07-04